Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01038427 · ClinicalTrials.gov registry record · Phase 3

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

A Phase 3 study of Rhinitis, Allergic, Seasonal, sponsored by Sandoz.

Completed
Registry status
Phase 3
Development phase
795
Enrollment target
8
Study locations

NCT01038427: Completed Phase 3 study of Rhinitis, Allergic, Seasonal, sponsored by Sandoz.

NCT01038427 is a Phase 3 study of Rhinitis, Allergic, Seasonal that has completed, run by Sandoz. The registered enrollment target is 795 participants, above the 594-participant average among 3 other Rhinitis, Allergic, Seasonal trials with a reported enrollment target (34% higher). The trial reports 8 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01038427, a Phase 3 study of Rhinitis, Allergic, Seasonal, has completed, sponsored by Sandoz.

COMPLETED
Registry status
Phase 3
Development phase
795 participants
Enrollment target
8
Study locations

Study Summary

This study compared the efficacy and safety of a generic mometasone nasal spray to the reference listed drug in the treatment of seasonal allergic rhinitis. Additionally both the test and the reference formulations were tested for superiority against a placebo nasal spray.

Primary Outcome

Patients were required to record a 12 hour "reflective" score twice a day approximately 12 hours apart. For the rTNSS patients were asked to "look back" or "reflect" on their severity of nasal symptoms over the previous 12 hours. The first rating on each day was taken prior to dosing. Patients were asked to score 4 nasal symptoms (nasal congestion, runny nose, sneezing and itchy nose) on a 4 point scale ranging from 0 (no symptom) to 3 (severe symptom). The means of the 4 individual symptom scor

Interventions

  • DRUG Placebo
  • DRUG Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)
  • DRUG Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray

Study Locations (8)

Texas

  • - Austin
  • - Austin
  • - Kerrville
  • - Live Oak
  • - New Braunfels
  • Sylvana Research - San Antonio
  • - San Antonio
  • - Waco

Trial Details

FieldValue
Enrollment Target 795 participants
Start Date 2009-12-02
Est. Completion 2010-02-16
Phase Phase 3
Sandoz

29 total trials

What the finished NCT01038427 record still lists

NCT01038427 is an interventional study that assigns participants to a tested intervention. The registered 795 participants enrollment target is mid-sized for trials with a published cap, above the 594-participant average among 3 other Rhinitis, Allergic, Seasonal trials with a reported enrollment target (34% higher).

The record links to 1 condition, with Rhinitis, Allergic, Seasonal appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01038427 lists 8 locations in 1 state (Texas).

Frequently Asked Questions

What is clinical trial NCT01038427 about?

NCT01038427 is a clinical study titled "A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis". This study compared the efficacy and safety of a generic mometasone nasal spray to the reference listed drug in the treatment of seasonal allergic rhinitis. Additionally both the test and the reference formulations were tested for superiority against a placebo nasal spray.

What is the current status of trial NCT01038427?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 795 participants. The study started on 2009-12-02. Estimated completion is 2010-02-16.

What conditions does trial NCT01038427 study?

This clinical trial studies the following conditions: Rhinitis, Allergic, Seasonal.

What interventions are being tested in trial NCT01038427?

The interventions under investigation include: Placebo (DRUG), Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals) (DRUG), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray (DRUG).

Who is sponsoring clinical trial NCT01038427?

This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01038427 being conducted?

This trial has 8 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rhinitis, Allergic, Seasonal

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06208150 · 795 participants · Phase 3

    A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  • NCT06724172 · 795 participants · NA

    CHIME: Comparing Health Interventions for Maternal Equity

  • NCT05150691 · 796 participants · Phase 1

    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

  • NCT06051058 · 798 participants · NA

    Care Transitions App for Patients With Multiple Chronic Conditions

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01038427, the US trial registry maintained by the National Library of Medicine. NCT01038427 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.